This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with ovarian cancer. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
This guideline includes recommendations on:
- detection in primary care
- establishing the diagnosis in secondary care
- management of suspected early (stage I) ovarian cancer
- management of advanced (stage II–IV) ovarian cancer
- support needs of women with newly diagnosed ovarian cancer
Who is it for?
- Healthcare professionals
- Commissioners and providers
- People who provide palliative and hospice care for the NHS
- Women with ovarian cancer and their families and carers
Is this guideline up to date?
We checked this guideline in November 2017 and will not update it.
Guideline development process
The recommendations in section 1.1 on detection in primary care have been incorporated into NICE guideline NG12 (June 2015). Recommendation 18.104.22.168 in this guideline partially replaces recommendation 22.214.171.124 in NICE guideline CG61 (February 2008).
This guideline was previously called ovarian cancer: the recognition and initial management of ovarian cancer.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.